AACT Antibody (804): sc-59432
- AACT Antibody (804) is a mouse monoclonal IgG2a provided at 100 µg/ml
- raised against AACT from serum of human origin
- recommended for detection of AACT of human origin by WB, IP and ELISA; non cross-reactive with α1 antitrypsin
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for AACT Antibody (804). This work is in progress.
QUICK LINKS
SEE ALSO...
AACT Antibody (804) is a mouse monoclonal IgG2a antibody that detects AACT in human samples through applications such as western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). AACT, also known as alpha-1-antichymotrypsin, plays a crucial role as a serine proteinase inhibitor, primarily synthesized in the liver as a single glycopeptide chain. Anti-AACT antibody (804) helps researchers study vital physiological processes, including inflammation and tissue repair, as AACT modulates the activity of proteases that can otherwise lead to tissue damage if left unchecked. The structure of AACT features a unique reactive center loop that allows effective inhibition of serine proteases, thereby preventing excessive proteolytic activity during acute phase responses. AACT levels can significantly increase in response to trauma, surgery, or infection, making AACT a key player in the body′s defense mechanisms. Elevated AACT levels have been associated with neurodegenerative conditions such as Alzheimer′s disease, highlighting AACT′s potential as a biomarker for disease progression. AACT (804) monoclonal antibody serves as an essential tool for researchers investigating AACT′s role in various pathological conditions, including interactions with other proteins like prostate-specific antigen, which is commonly used in prostate cancer diagnostics.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
AACT Antibody (804) References:
- Association of serum AACT levels and AACT signal polymorphism with late-onset Alzheimer's disease in Northern Ireland. | McIlroy, SP., et al. 2000. Int J Geriatr Psychiatry. 15: 260-6. PMID: 10713585
- [Analysis of the polymorphisms of the AACT, ERAB and NACP genes in 15 patients with Alzheimer's disease]. | Cui, S., et al. 2001. Zhonghua Yi Xue Za Zhi. 81: 90-2. PMID: 11798857
- A physical map of the human PI and AACT genes. | Sefton, L., et al. 1990. Genomics. 7: 382-8. PMID: 1973140
- Comparative analysis of the human urinary proteome by 1D SDS-PAGE and chip-HPLC-MS/MS identification of the AACT putative urinary biomarker. | Zhang, Y., et al. 2010. J Chromatogr B Analyt Technol Biomed Life Sci. 878: 3395-401. PMID: 21093387
- Methodology for AACT evidence-based recommendations on the use of intravenous lipid emulsion therapy in poisoning. | Gosselin, S., et al. 2015. Clin Toxicol (Phila). 53: 557-64. PMID: 26059735
- Aggretin Venom Polypeptide as a Novel Anti-angiogenesis Agent by Targeting Integrin alpha2beta1. | Chung, CH., et al. 2017. Sci Rep. 7: 43612. PMID: 28252668
- Loperamide toxicity: recommendations for patient monitoring and management. | Eggleston, W., et al. 2020. Clin Toxicol (Phila). 58: 355-359. PMID: 31684751
- Alpha-1-antichymotrypsin as a novel biomarker for diagnosis, prognosis, and therapy prediction in human diseases. | Jin, Y., et al. 2022. Cancer Cell Int. 22: 156. PMID: 35439996
- Machine learning-based analysis identifies and validates serum exosomal proteomic signatures for the diagnosis of colorectal cancer. | Yin, H., et al. 2024. Cell Rep Med. 5: 101689. PMID: 39168094
- Increased plasma AACT level as an indicator of poor prognosis in patients hospitalised with community-acquired pneumonia: a multicentre prospective cohort study. | Zhao, L., et al. 2024. BMC Infect Dis. 24: 946. PMID: 39251931
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
AACT Antibody (804) | sc-59432 | 100 µg/ml | $322.00 |